Bristol-Myers Squibb clarification on didanosine supply.

摘要

In response to an open letter to Bristol-Myers Squibb from board members of UNITAID (June 26, p 2213), below are important clarifications regarding the supply of didanosine. Bristol-Myers Squibb is committed to helping ensure paediatric patients remain on treatment. There is no supply shortage at this time and we expect being able to provide uninterrupted access to didanosine. The supply risk for didanosine 25 mg and 50 mg tablets is a result of a striking increase in demand for didanosine, despite supply forecasts we requested from purchasing organisations and the absence of changes in treatment guidelines. There is no supply risk for other forms of didanosine.